Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 65.24 Billion | USD 82.92 Billion | 2.7% | 2023 |
According to the report published by Zion Market Research, the global Anti-Rheumatics Market size was valued at USD 65.24 Billion in 2023 and is predicted to reach USD 82.92 Billion by the end of 2032. The market is expected to grow with a CAGR of 2.7% during the forecast period. The report analyzes the global Anti-Rheumatics Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Anti-Rheumatics industry.
Rheumatoid arthritis is a medical disorder that is indicated by the presence of swollen, warm, and painful joints. The disease affects both the hand and wrist of the person. Rheumatoid arthritis disorder continuously proliferates over a period of time. The treatment is done using various drugs known as anti-rheumatic. Such drugs are known to modify the course of medical conditions. However, the disease-modifying anti-rheumatic drugs are the ones that slow down the spread and progression of the disease. Different drugs like anti-inflammatory and non-steroidal drugs are utilized in the treatment process of rheumatoid arthritis.
The easy availability of novel biologics along with the growing reliable clinical treatments is one of the major factors driving the growth of the global anti-rheumatics market vigorously. The growing awareness among people regarding safer drugs is the key reason inclining patients toward the anti-rheumatics. However, the disease is continuously progressing rapidly all across the globe.
Thus, the government regulatory bodies and the prominent market players are boosting their funding to develop effective drugs against rheumatoid arthritis to lower its incidences all over the world. Also, the presence of biologics and biosimilars along with the increasing acceptance of biopharmaceuticals is likely to trigger the growth of the market during the forecast period. The emergence of combination therapy to provide advanced and positive results to patients is expected to positively shape the trajectory of the global anti-rheumatics market during the forecast period.
The global anti-rheumatics market can be segmented into the sales channel, molecule type, and region.
By sales channel, the market can be segmented into over-the-counter and prescription. The prescription segment accounts for the largest share in the global anti-rheumatics market due to the growing awareness among patients regarding advanced disease reversal treatment methods and techniques. Also, the growing consultations for rheumatoid arthritis by medical professionals are likely to further augment the growth of the segment in the forthcoming years. However, the growing adverse effect of over-the-counter medication in patients also fueled the growth of the segment. However, the continuous intake of over-the-counter medication for pain management leads to liver damage and medication addiction which is also likely to promulgate the growth of the segment.
By molecule type, the market can be segmented into biopharmaceutical and pharmaceuticals. The pharmaceutical segment can further be bifurcated into glucocorticoids, DMARDs, analgesics, and NSAIDs. The biopharmaceutical segment is further bifurcated into biosimilars and biologics. The biopharmaceuticals segment holds the largest share in the global anti-rheumatics market due to the growing number of novel biotherapies and treatments for rheumatoid arthritis. However, the pharmaceutical segment is also expecting to grow vigorously during the forecast period due to the fact that it is considered a first-line treatment for such medical disorders. The biologics segment holds hegemony over others. The biologics segment is further categorized into anti-IL 6 biologics, JAK inhibitors, CD20 antigen, T-cell inhibitors, and TNF-α antagonists.
Report Attributes | Report Details |
---|---|
Report Name | Anti-Rheumatics Market |
Market Size in 2023 | USD 65.24 Billion |
Market Forecast in 2032 | USD 82.92 Billion |
Growth Rate | CAGR of 2.7% |
Number of Pages | 193 |
Key Companies Covered | Amgen Inc., Celltrion Inc., Biogen Inc., Takeda Pharmaceutical Company Ltd., MedImmune, LLC, Celgene Corporations, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson, and Pfizer, Inc |
Segments Covered | By sales channel, By molecule type and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America accounts for the largest share in the global anti-rheumatics market due to the growing awareness among patients regarding the easy availability of effective treatments in the region. Moreover, the growing incidences of rheumatoid arthritis in the region will further augment the growth of the regional market in the forthcoming years. Also, the growing expenditure from the governments as well as the prominent market players to strengthen the healthcare infrastructure is further likely to stimulate the growth of the regional market.
Asia Pacific is anticipated to witness significant growth during the forecast period due to the high adoption of urbanic lifestyle among people in the region.
Some of the significant players in the global anti-rheumatics market are
By Sales Channel
By Molecule Type
FrequentlyAsked Questions
The easy availability of novel biologics along with the growing reliable clinical treatments is one of the major factors driving the growth of the global anti-rheumatics market vigorously. The growing awareness among people regarding safer drugs is the key reason inclining patients toward the anti-rheumatics. However, the disease is continuously progressing rapidly all across the globe.
Some of the significant players in the global anti-rheumatics market are Amgen Inc., Celltrion Inc., Biogen Inc., Takeda Pharmaceutical Company Ltd., MedImmune, LLC, Celgene Corporations, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson, and Pfizer, Inc.
North America accounts for the largest share in the global anti-rheumatics market due to the growing awareness among patients regarding the easy availability of effective treatments in the region. Moreover, the growing incidences of rheumatoid arthritis in the region will further augment the growth of the regional market in the forthcoming years.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed